The merit of proton magnetic resonance spectroscopy in the longitudinal assessment of spinocerebellar ataxias and multiple system atrophy-cerebellar type

Table 3 The differences in MRS metabolites between patient groups at the 1 ^st MRS assessment

		Disease	SCA3 ^*	SCA6 ^*	MSA-C ^*
Cerebellar hemispheres	NAA/Cr	SCA2	0.000	0.004	0.155
		SCA3	-	0.356	0.000
		SCA6	-	-	0.000
	Cho/Cr	SCA2	0.010	0.039	0.035
		SCA3	-	0.985	0.000
		SCA6	-	-	0.002
	NAA/Cho	SCA2	0.236	0.606	0.743
		SCA3	-	0.356	0.018
		SCA6	-	-	0.401
Vermis	NAA/Cr	SCA2	0.037	0.297	0.013
		SCA3	-	0.487	0.000
		SCA6	-	-	0.024
	Cho/Cr	SCA2	0.256	0.180	0.064
		SCA3	-	0.252	0.001
		SCA6	-	-	0.011
	NAA/Cho	SCA2	0.730	0.456	0.493
		SCA3	-	0.158	0.092
		SCA6	-	-	0.665

SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy- cerebellar type.
*Mann–Whitney test, p-value.

ISSN: 2053-8871